CXCR4 and osteosarcoma: They used the CXCR4 antagonist AMD3100 to block the binding of SDF-1 to CXCR4, which significantly reduced the infiltration of MDSCs in osteosarcoma and had a synergistic effect when combined with anti-PD-1 antibodies, a novel option for immunotherapy of osteosarcoma.